drugset / Trial / NCT00860275

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

NCT00860275

Phase 1 Completed 30 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of the study is to determine if the concomitant administration of either ketoconazole or fluconazole with BMS-708163 will affect the PK of BMS-708163 and to assess safety and tolerability of BMS-708163

Timeline

Start
2009-04
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Avagacestat Small molecule 50 mg Oral
Comparator Fluconazole Small molecule 200 mg Oral
Comparator Ketoconazole Small molecule 400 mg Oral

Indications